News

INC signs on to help Provectus get its regulatory act together

Provectus Biopharmaceuticals, a biotech that has been stung by regulatory setbacks, has recruited INC Research to audit its data on two drug candidates, tasking the CRO with poring over its documents as it moves into late-stage development.

Catalent reaches out to lung cancer patients with research agreement

Catalent has partnered with the Lung Cancer Alliance to survey patients on how they manage the disease and deal with treatment compliance, an effort to highlight unmet needs and match them with new dosage forms.

Covance and Novartis team up with eyes on Big Data

Covance has joined forces with Novartis to develop new ways to help drug developers quickly integrate and analyze huge swaths of study data.

Parexel expands in the U.K. after an eClinical buyout

Parexel International is widening its presence in Nottingham, U.K., tapping local grant funds to consolidate some outposts with plans to grow around its latest acquisition.

Clinipace raises $4M after staging 5 buyouts in 5 years

North Carolina CRO Clinipace has raised $4 million, and while the company isn't disclosing why it needs the cash, the move follows years of dealmaking and could be a prelude to another buyout.

With help from Charles River, AstraZeneca expands its respiratory pipeline

AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.

European CRO Genae stretches out in the U.S.

Belgian researcher Genae has expanded its U.S. presence with an office in New York City, part of its strategy to capitalize on the North American market for clinical trials.

Accelovance poaches a Big Pharma vet to lead its oncology efforts

Early-phase CRO Accelovance has landed a former Pfizer and Otsuka exec to flesh out its efforts in oncology, part of a sweeping growth strategy that has seen the company expand across the U.S.

Chiltern picks up an Asian CRO with eyes on oncology

CRO Chiltern has reached into Singapore for its latest acquisition, buying out an Asian clinical contractor to expand its geographic footprint and therapeutic reach.

Catalent bets on armed antibodies with Redwood buyout

In its first acquisition since going public over the summer, Catalent has bought up longtime partner Redwood Bioscience, bringing in proprietary technology for developing antibody-drug conjugates.

WuXi snags a stateside CRO to beef up its early-stage services

Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.

Parexel buys a U.K. tech outfit to expand its eClinical biz

Parexel International has bought up the U.K.'s ClinIntel, a supply chain software outfit that should fit right in with the CRO's growing technology business.

AstraZeneca moves away from outsourcing, at least in IT

AstraZeneca is looking to bring more of its IT work in-house, spending money to stand up an Indian hub that will replace much of its contract spend in the field.

Post-IPO Ergomed keeps rolling with its risk-sharing partnerships

U.K. drug development outfit Ergomed has come out the other end of its London IPO, touting a range of R&D partnerships that give it a chance to share the rewards of its clients' work.

Catalent partners up with Cingulate on two ADHD drugs

The recently IPO'd Catalent has signed a deal with biotech Cingulate Therapeutics to help develop a duo of candidates for ADHD, tapping its expertise in crafting controlled-release tablets.

Evotec lends its R&D might to the multiple sclerosis cause

Germany's Evotec has joined a trio of research projects focused on multiple sclerosis, contributing its developmental know-how to some early-stage R&D.

GVK accused of tampering with data in Indian clinical trials

Indian CRO GVK Biosciences is working to get back in the good graces of European regulators after inspectors found evidence that its employees doctored clinical trial results.

PPD bets on drug discovery with X-Chem deal

PPD is buying up the entirety of X-Chem, which operates as a biotech within a CRO, marking a vote of confidence in the continued demand for drug discovery services.

TransCelerate dishes on risk-based monitoring

TransCelerate BioPharma, a nonprofit founded by the world's biggest drugmakers to make R&D more efficient, is encouraging developers to adopt risk-based monitoring for clinical trials, disclosing its thinking in two research papers.

CRO FlowMetric gets into diagnostics with new spinout

Pennsylvania CRO FlowMetric is zeroing in on companion diagnostics, launching a new company to put its platform technology to use in developing tests.